glp-1 options for type 2 diabetes and obesity 2025 What are GLP-1s? GLP-1-based therapies for type 2

SubQ technology creates a new moat to protect brand name drugs, even as underlying patents on agents expire and biosimilars are approved, because subQ technology is not universally available and new subQ co-formulation patents are being issued to protect branded drugs

For related cellular wellness support, learn more about NAD+ IV therapy

Research suggests that there may be differences in GLP-1 response between men and women

Research also suggests that thiamin acts as an antioxidant, protecting nerves from oxidative damage that can lead to cell death and degeneration

While delayed gastric emptying is possible with all GLP-1s, including semaglutides like Ozempic, Wegovy, and Rybelsus, the other types do not come with a formal warning